Vmn2r90 Inhibitors
Vmn2r90 inhibitors are a class of chemical agents that specifically target and inhibit the activity of a particular receptor known as Vmn2r90. This receptor belongs to a larger family of Vomeronasal type 2 receptors (V2Rs), which are a group of G protein-coupled receptors (GPCRs) that can be found in the vomeronasal organ (VNO) of certain mammals. The VNO is an olfactory system structure that is implicated in the detection of pheromones, chemical compounds that play a role in inter-animal communication by conveying information about the physiological or emotional state of an individual. Vmn2r90 inhibitors, therefore, interact with these receptors at a molecular level, affecting the normal binding process of their natural ligands, which are typically various forms of pheromones or similar chemical substances.
The mechanism of action for Vmn2r90 inhibitors involves the binding of these inhibitory molecules to the Vmn2r90 receptor in such a way that they prevent the natural ligand from associating with the receptor's active site. This blockade impedes the usual signal transduction pathways that would ordinarily be initiated by the receptor-ligand interaction. By obstructing these pathways, Vmn2r90 inhibitors effectively modulate the molecular processes that would follow such a binding event, which can include a cascade of intracellular signaling resulting in various biochemical responses. The specific molecular structure of these inhibitors is designed to afford them a high degree of selectivity for the Vmn2r90 receptor, ensuring that their inhibitory action is as targeted as possible in order to minimize off-target effects that could arise from interaction with other receptor types within the V2R family or other GPCRs. The development and refinement of Vmn2r90 inhibitors are grounded in advanced understanding of receptor pharmacology and molecular interactions, making it a field that heavily relies on sophisticated techniques in molecular biology, chemistry, and computational modeling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine is known to inhibit cytochrome P450 enzymes, which are involved in a plethora of metabolic pathways. By altering the metabolism of certain ligands or signaling molecules, quinine may indirectly affect the signaling pathways in which Vmn2r90 is involved, leading to its functional inhibition. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Lidocaine is a sodium channel blocker and local anesthetic. By blocking sodium channels, lidocaine may inhibit neuronal excitability and, as a consequence, may indirectly decrease the functional activity of Vmn2r90, which is expressed in chemosensory neurons. | ||||||
Methimazole | 60-56-0 | sc-205747 sc-205747A | 10 g 25 g | $70.00 $112.00 | 4 | |
Methimazole inhibits thyroid peroxidase, leading to decreased thyroid hormone production. Thyroid hormones can modulate neuronal sensitivity, which might affect the function of Vmn2r90 indirectly by altering the chemosensory system's responsiveness. | ||||||
Reserpine | 50-55-5 | sc-203370 sc-203370A | 1 g 5 g | $137.00 $414.00 | 1 | |
Reserpine depletes monoamine neurotransmitters by inhibiting vesicular monoamine transporters. This depletion may influence the signaling pathways that Vmn2r90 is part of, indirectly leading to a decrease in its functional activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, can inhibit calcium influx into cells, potentially affecting calcium-dependent signaling pathways. These pathways may be indirectly related to Vmn2r90's role in chemosensory signal transduction, leading to inhibition of its activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a beta-adrenergic receptor antagonist. By blocking beta-adrenergic receptors, it may alter adrenergic signaling pathways that could indirectly influence the functional activity of Vmn2r90. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Ondansetron is a serotonin 5-HT3 receptor antagonist. Serotonin signaling can modulate sensory neuron function, and by blocking 5-HT3 receptors, ondansetron might indirectly affect the signaling pathways involving Vmn2r90. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is another calcium channel blocker that can modify intracellular calcium levels and related signaling pathways. These pathways could intersect with those involving Vmn2r90, leading to a decrease in the protein's activity. | ||||||
5,5-Diphenyl Hydantoin | 57-41-0 | sc-210385 | 5 g | $70.00 | ||
Phenytoin is a sodium channel blocker that can dampen neuronal excitability. By influencing sodium-dependent action potentials, phenytoin might indirectly decrease the activity of Vmn2r90 in the context of neuronal signaling. | ||||||
Tetracaine | 94-24-6 | sc-255645 sc-255645A sc-255645B sc-255645C sc-255645D sc-255645E | 5 g 25 g 100 g 500 g 1 kg 5 kg | $66.00 $309.00 $500.00 $1000.00 $1503.00 $5000.00 | ||
Tetracaine is a local anesthetic that blocks voltage-gated sodium channels. Its action may lead to a reduction in neuronal signaling capacity, which could indirectly reduce the functional activity of Vmn2r90. | ||||||